terça-feira, abril 05, 2005
FDA aprova novo medicamento contra hepatite B
The US Food and Drug Administration (FDA) announced yesterday that on March 29th it approved entecavir, marketed by Bristol-Myers Squibb (BMS) as Baraclude, for the treatment of chronic hepatitis B virus for individuals monoinfected with hepatitis B and individuals coinfected with both HIV and hepatitis B who have previously received 3TC (lamivudine, Epivir/Zeffix).
(...)
